With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world... Show more
NVO is expected to report earnings to fall 85.97% to 88 cents per share on May 07
Q1'25
Est.
$0.89
Q4'24
Beat
by $5.46
Q3'24
Beat
by $5.24
Q2'24
Beat
by $9.46
Q1'24
Beat
by $4.93
The last earnings report on February 05 showed earnings per share of $6.34, beating the estimate of 87 cents. With 858.00K shares outstanding, the current market capitalization sits at 299.64B.